Company Profile
Dyne Therapeutics Stock Price, News & Catalysts
- Ticker:
- DYN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
26.10 USD (+0.46%)
Close
Last updated: August 21, 2026
2.85B USD
Market cap
Why the stock is moving
The latest company update was “Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. DYN changed 0.46% and closed at $26.10 on Aug 21, 2026, indicating a relatively limited closing-price reaction to this company update.
Company overview
Oligonucleotide Therapeutics
Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue.
Duchenne Muscular Dystrophy
Z-rostudirsen is designed for patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The candidate has completed the registrational portion of the DELIVER program, and Dyne is preparing it for regulatory submission and commercialization.
Myotonic Dystrophy
Z-basivarsen targets toxic DMPK RNA in myotonic dystrophy type 1. It is being evaluated in the Phase 1/2 ACHIEVE study and the global confirmatory Phase 3 HARMONIA trial.
Future catalysts
- BLA submission for z-rostudirsen in the second quarter of 2026.
- Completion of enrollment in the registrational ACHIEVE expansion cohort for z-basivarsen in the second quarter of 2026.
- Potential U.S. launch of z-rostudirsen in the first quarter of 2027, subject to approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Dyne Therapeutics (DYN)?
Dyne Therapeutics (DYN) most recently closed at 26.10 USD, a +0.46% move versus the previous session.
What is the market cap of Dyne Therapeutics (DYN)?
Dyne Therapeutics currently has a market capitalization of 2.85B USD on BioPharmSignal.
What does Dyne Therapeutics do?
Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue. Duchenne Muscular Dystrophy Z-rostudirsen is designed for patients with Duchenne muscular dystrophy amenable to exon 51...
On which exchange is DYN stock listed?
Dyne Therapeutics (DYN) is associated with NASDAQ, United States, Biopharma.
What is Oligonucleotide?
Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases.
Which conditions is Dyne Therapeutics targeting with Oligonucleotide?
Dyne Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Dyne Therapeutics describe recent progress with Oligonucleotide?
BLA submission for z-rostudirsen in the second quarter of 2026. Completion of enrollment in the registrational ACHIEVE expansion cohort for z-basivarsen in the second quarter of 2026. Potential U.S. launch of z-rostudirsen in the first quarter of 2027, subject to approval.
What is Therapeutics?
Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases.